StockDriftsStockDriftsCellomax Science (471820) has 9 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩288M ($200K) in reported transaction value. The earliest filing StockDrifts holds for Cellomax Science is dated 2024-12-13; the most recent is 2026-04-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +12.60%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | BUY | 자사주상여금 | 서지혜 Jihye Seo | moving | 5.0K | ₩4,950 | +7.5% | ₩25M ($17K) |
| 2026-04-01 | BUY | 자사주상여금 | 양인규 Yang In-gyu | Managing Director | 10.2K | ₩4,950 | +7.5% | ₩50M ($35K) |
| 2026-04-01 | BUY | 자사주상여금 | 서지완 Seo Ji-wan | Managing Director | 2.0K | ₩4,950 | +7.5% | ₩10M ($7K) |
| 2026-01-21 | BUY | Market Buy | 김성락 Seongrak Kim | president | 10.0K | ₩4,830 | +12.2% | ₩48M ($34K) |
| 2026-01-01 | BUY | 신규선임 | 서지혜 Jihye Seo | moving | 611.5K | ₩6,970 | -22.2% | ₩4.3B ($3.0M) |
| 2025-07-15 | BUY | Market Buy | 김성락 Seongrak Kim | president | 9.8K | ₩5,380 | +0.7% | ₩53M ($37K) |
| 2025-07-14 | BUY | Market Buy | 김성락 Seongrak Kim | president | 202 | ₩5,510 | -1.6% | ₩1M ($773) |
| 2025-07-04 | BUY | Market Buy | 김성락 Seongrak Kim | president | 10.0K | ₩4,735 | +14.5% | ₩47M ($33K) |
| 2025-04-11 | BUY | Market Buy | 김성락 Seongrak Kim | president | 1.9K | ₩4,600 | +17.8% | ₩9M ($6K) |
| 2025-04-10 | BUY | Market Buy | 김성락 Seongrak Kim | president | 497 | ₩4,670 | +16.1% | ₩2M ($2K) |
| 2025-04-09 | BUY | Market Buy | 김성락 Seongrak Kim | president | 7.6K | ₩4,665 | +16.2% | ₩35M ($25K) |
| 2025-04-02 | BUY | Market Buy | 김성락 Seongrak Kim | president | 4.2K | ₩4,500 | +20.4% | ₩19M ($13K) |
| 2025-04-01 | BUY | Market Buy | 김성락 Seongrak Kim | president | 15.8K | ₩4,630 | +17.1% | ₩73M ($51K) |
| 2025-04-01 | BUY | 자사주상여금 | 양인규 Yang In-gyu | Managing Director | 10.2K | ₩4,630 | +17.1% | ₩47M ($33K) |
| 2025-04-01 | BUY | 자사주상여금 | 서지완 Seo Ji-wan | Managing Director | 2.0K | ₩4,630 | +17.1% | ₩9M ($7K) |
| 2024-12-13 | BUY | 신규상장 | 서정민 Seo Jeong-min | CEO | 4.1M | ₩7,960 | -31.9% | ₩32.7B ($22.7M) |
| 2024-12-13 | BUY | 신규상장 | 문민선 Moon Min-seon | - | 2.8M | ₩7,960 | -31.9% | ₩22.0B ($15.3M) |
| 2024-12-13 | BUY | 신규상장 | 김성락 Seongrak Kim | president | 100.0K | ₩7,960 | -31.9% | ₩796M ($553K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Cellomax Science. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.